BIORA THERAPEUT.NEW -001
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more
BIORA THERAPEUT.NEW -001 (4ZU0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BIORA THERAPEUT.NEW -001 (4ZU0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BIORA THERAPEUT.NEW -001 - Net Assets Trend (None–None)
This chart illustrates how BIORA THERAPEUT.NEW -001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BIORA THERAPEUT.NEW -001 (None–None)
The table below shows the annual net assets of BIORA THERAPEUT.NEW -001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BIORA THERAPEUT.NEW -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BIORA THERAPEUT.NEW -001 Competitors by Market Cap
The table below lists competitors of BIORA THERAPEUT.NEW -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Current Water Technologies Inc
PINK:ENPRF
|
$1.93 Million |
|
HN30
F:HN30
|
$1.93 Million |
|
REPUBLIC SERVICES (RPU.SG)
STU:RPU
|
$1.93 Million |
|
RanLOS AB Series B
ST:RLOS-B
|
$1.93 Million |
|
Marvel Discovery Corp
OTCQB:MARVF
|
$1.92 Million |
|
HERSHEY - Dusseldorf Stock Exchang
DU:HSY
|
$1.92 Million |
|
Danasupra Erapacific Tbk
JK:DEFI
|
$1.92 Million |
|
Parabellum Resources Ltd
AU:PBL
|
$1.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIORA THERAPEUT.NEW -001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BIORA THERAPEUT.NEW -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BIORA THERAPEUT.NEW -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BIORA THERAPEUT.NEW -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIORA THERAPEUT.NEW -001 (4ZU0) | €- | N/A | N/A | $1.93 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |